PubMed Health⌕ Search

Biomedical subjects

James A Simon

Publications and source records attributed to James A Simon.

21 records · Page 2Linked to original sources

Monitoring reproductive aging in a 5-year prospective study: aggregate and individual changes in luteinizing hormone and follicle-stimulating hormone with age.

OBJECTIVE: This study describes age-related changes in luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in a 5-year prospective study of reproductive aging. DESIGN: Participants (n = 156 college-educated, white, US women; 25 to 58 y) were recruited from the TREMIN Research Program on Women's Health. They collected daily urine specimens for 6 months in each of 5 consecutive years. Specimens were assayed for LH and FSH. Aggregate changes were calculated in LH and FSH with age, and multilevel models were used to estimate individual hormone trajectories and within-woman and between-woman variances by age. RESULTS: Aggregate LH levels increased beginning after age 45; FSH increased at all ages, accelerating after age 45. Individual-level patterns with age included the following: reproductive-age LH and FSH levels, with increasing FSH and increasing or decreasing LH (ages 20 to 49); rapidly increasing LH and FSH (ages 40 to 59); and increasing or steady postmenopausal LH and FSH (ages 46 to 62). FSH levels were consistently high in the latter category, but LH levels overlapped with levels found in younger women (<45 y). Individual LH patterns showed more variability (5% to 35% of total variance) than FSH (3% to 22% of total variance). Both hormones had relatively low variation within individuals compared with between-woman differences (65% to 97% of total variance). CONCLUSIONS: Aggregate-level data do not reflect differences across women and oversimplify the age-related increases and variability in LH and FSH. Individual FSH levels are not distinguishable from reproductive-age levels until after rapid perimenopausal increases in FSH occur; individuals vary in whether their postmenopausal LH levels are distinguishable from reproductive-age levels.

Adult↗

Counseling patients who elect to discontinue hormone therapy.

Following the reports of the Heart and Estrogen/Progestin Replacement (HERS) Trial and the Women's Health Initiative (WHI), many women abruptly discontinued their hormone therapy. This withdrawal of estrogen causes physiological changes, some changes which are short-term and obvious (i.e., hot flashes, night sweats) and other changes that are more subtle and lead to long-term problems (i.e., loss of bone density, increased risk of fracture). Health care providers need to be prepared to discuss alternative therapies available to women who have recently stopped estrogen therapy. Practitioners today have many more, and better, therapeutic choices to prevent osteoporosis than ever before. Counseling patients on which treatment options: raloxifene, bisphosphonate, calcitonin, or PTH are most appropriate for their situation is important to long-term compliance and a satisfactory reduction in fracture risk.

Calcitonin↗

Treatment of osteoporosis: combination therapies.

Several classes of medication are available for the prevention and/or treatment of osteoporosis including reproductive hormones, bisphosphonates, selective estrogen-receptor modulators, calcitonin and most recently parathyroid hormone. These medications, acting through different mechanisms, have been shown to preserve or increase bone mineral density and some ultimately reduce osteoporotic fracture. The benefits of these individual therapeutic approaches appear limited leading some investigators to use the agents in combination in an effort to achieve additional effects. Few studies looking at the effects of combination therapies are currently available for review. While the results of the available studies are generally positive, they lack the statistical power to satisfactorily demonstrate any additional contribution to fracture reduction. The potential synergistic effects of combination therapies are just beginning to be explored. Until more information is available, recommendations for use of combination therapies should be limited to specific clinical situations.

Alendronate↗